Closing Remarks
AASLD LiverLearning®, Zobair Younossi, 170278
Summary of the Meeting: What to Do Next?
AASLD LiverLearning®, Keith Lindor, 170277
Emerging Therapy for NASH: Antifibrotics
AASLD LiverLearning®, Scott Friedman, 169510
Emerging Therapy for NASH: Non-antifibrotics
AASLD LiverLearning®, Stephen Harrison, 169509
Weight Loss and Exercise in NAFLD
AASLD LiverLearning®, Jacob George, 169507
What Are the Best Endpoints for the Clinical Trials of NASH: Investigator and Regulatory Perspective
AASLD LiverLearning®, Kris Kowdley, 169506
Serum Fibrosis Markers in NASH
AASLD LiverLearning®, Quentin Anstee, 169505
Noninvasive Biomarkers in NASH
AASLD LiverLearning®, Naga Chalasani, 169504
Role of Histopathology in the Clinical Research and Clinical Management of Patients with NAFLD
AASLD LiverLearning®, Zachary Goodman, 169502
VLX103, a New Hepatoselective Investigational Drug Targeting the LPS-TLR4 Pathway in Non-Alcoholic Liver Disease
AASLD LiverLearning®, Patrick Colin, 170269
Predicting the degree of liver-biopsy-confirmes steatosis and fibrosis using transient elastography and magnetic resonance imaging-based techniques in adult patients with suspected non-alcoholic fatty liver disease
AASLD LiverLearning®, Stephen Harrison, 170267
Nonalcoholic Fatty Liver Disease in Children: Not a Tiny Matter
AASLD LiverLearning®, Joel Lavine, 169499
Racial and Ethnic Differences in Nonalcoholic Fatty Liver Disease
AASLD LiverLearning®, Arun Sanyal, 169498
NAFLD and Microbiome
AASLD LiverLearning®, Kathleen Corey, 169495
The Role of Mitochondria and Endoplasmic Reticulum in NASH Pathogenesis
AASLD LiverLearning®, Stephen Caldwell, 169493
Session II: Metabolic Syndrome and NASH : Q&A
AASLD LiverLearning®, Session Speakers, 170256
Cardiovascular Diseases and NAFLD
AASLD LiverLearning®, Francesco Negro, 169492
Insulin Resistance in NAFLD
AASLD LiverLearning®, Brent Tetri, 169490
Is MS the Consequence or Precursor of NASH?
AASLD LiverLearning®, Giulio Marchesini, 169489
Q&A
AASLD LiverLearning®, Session Speakers, 169830
Will the Epidemic of NAFLD Be Responsible for the Future Burden of HCC?
AASLD LiverLearning®, Elisabetta Bugianesi, 169488
Long Term Outcomes: Mortality and Causes of Death in NAFLD
AASLD LiverLearning®, Mary Rinella, 169487
Clinical, Epidemiologic, Patient-Reported and Economic Burden of NAFLD
AASLD LiverLearning®, Zobair Younossi, 169486
Welcome and Opening Remarks
AASLD LiverLearning®, Zobair Younossi, 169828
Welcome and Opening Remarks
AASLD LiverLearning®, Keith Lindor, 169829
Laboratory‐based biomarkers to improve causality assessment in drug‐induced liver injury
AASLD LiverLearning®, Daniel Antoine, 171991
The role of the hepatopathologist in the assessment of drug‐induced liver injury
AASLD LiverLearning®, David Kleiner, 171992
Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis
AASLD LiverLearning®, Michael Trauner, 171993
What can we learn from other clinical settings on the influence of the gut microbiome on the brain?
AASLD LiverLearning®, Eamonn M. M. Quigley, 171994
Introduction and setting the scene: New nomenclature of hepatic encephalopathy and American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines
AASLD LiverLearning®, Jasmohan S. Bajaj, 171995
Overview of causality assessment in drug‐induced liver injury
AASLD LiverLearning®, Paul Hayashi, 171996
Portal Vein Thrombosis in Cirrhosis: Causes and Consequences
AASLD LiverLearning®, Stephen Caldwell and Juan C. Garcia-Pagan, 167449
Thrombosis and coagulopathy in the liver transplant candidate and recipient
AASLD LiverLearning®, R. Todd Stravitz, 169134
The highly sensitized, high MELD, simultaneous liver‐kidney or status 1A heart‐liver transplant candidate
AASLD LiverLearning®, Timucin Taner, 169135
Genetics in liver diseases: From diagnostics to precise therapy
AASLD LiverLearning®, Frank Lammert, 169136
Developing a liver cancer program in the nonacademic medical center
AASLD LiverLearning®, Kent Benner, 169137
Changes in united network for organ sharing policy for simultaneous liver‐kidney allocation
AASLD LiverLearning®, David Mulligan, 169138
Elastography to assess the stage of liver fibrosis in children: Concepts, opportunities, and challenges
AASLD LiverLearning®, Claude Sirlin, 169139
A framework to determine when liver transplantation is futile
AASLD LiverLearning®, Jennifer Lai, 165947
The changing face of hepatic encephalopathy: A projection for the next 5 years
AASLD LiverLearning®, Debbie L Shawcross, 165948
Treatment of chronic cholestasis: What we know and what we will know?
AASLD LiverLearning®, James Boyer, 165949
Managing encephalopathy in the outpatient setting
AASLD LiverLearning®, Radha Dhiman, 165950
Mechanisms of portal hypertension: Bench to bedside
AASLD LiverLearning®, Jordi Gracia‐Sancho, 165951
Novel approaches to the treatment of biliary atresia
AASLD LiverLearning®, Jorge A. Bezerra, 165952
Novel treatments targeting immune‐related mechanisms in primary biliary cholangitis
AASLD LiverLearning®, Pietro Invernizzi, 164849
How does the microbiome affect liver disease?
AASLD LiverLearning®, Herbert Tilg, 164850
Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma
AASLD LiverLearning®, Ali Canbay, 164851
The scope of hepatology practice outside the traditional academic medical center
AASLD LiverLearning®, Marcelo Kugelmas, 164852
Novel treatments in primary sclerosing cholangitis
AASLD LiverLearning®, Keith Lindor, 164853
Cystic Fibrosis–Related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology
AASLD LiverLearning®, Mario Strazzabosco, 164854
Clinical Hepatology Debrief
AASLD LiverLearning®, Arun Sanyal, 154738
Elimination of Hepatitis B: Is It possible?
AASLD LiverLearning®, Anna Lok, 154737
Hepatitis Debrief
AASLD LiverLearning®, Robert Brown, 154735
Pangenotypic Regimens and the Next Generation of HCV Treatment
AASLD LiverLearning®, Nancy Reau, 154728
Resistance Testing: Interpretation and Incorporation into Treatment Algorithms
AASLD LiverLearning®, Jordan Feld, 154727
Management of Acute Variceal Bleed
AASLD LiverLearning®, Shiv Kumar Sarin, 154734
Treatment of Persons Who Inject Drugs (PWID): Treatment as Prevention
AASLD LiverLearning®, Jason Grebely, 154726
Non-cirrhotic Portal Hypertension: Eastern Perspective
AASLD LiverLearning®, Hitoshi Maruyama, 154733
In memoriam: Maribel Rodrigez Torres
AASLD LiverLearning®, Norbert Brau, 155710
HCV Symposium: Challenges in the DAA Era: Program Chair
AASLD LiverLearning®, Norah Terrault, 154723
Patients with Renal Failure: When and How to Treat?
AASLD LiverLearning®, David Roth, 154725
TIPS: Is Early Intervention Helpful?
AASLD LiverLearning®, Florence Wong, 154732
Non-cirrhotic Portal Hypertension: Western Perspective
AASLD LiverLearning®, Theo Heller, 154731
AASLD-APASL Symposium: Portal Hypertension: Program Chair
AASLD LiverLearning®, Rajender Reddy, 154729
New Treatments for NASH
AASLD LiverLearning®, Brent Tetri, 154722
Advances in Non-invasive Assessment and Genetics of NAFLD
AASLD LiverLearning®, Christopher Paul Day, 154721
Advances in the Management of Alcoholic Liver Disease
AASLD LiverLearning®, Philippe MATHURIN, 154720
Impact of Pre-Existing Liver Disease on Treatment and Outcomes of Breast Cancer
AASLD LiverLearning®, Joseph Menzin, 144649
'Othello Hypothesis' Involved in the Development of NS5A-RAVs in Patients with Genotype 1b HCV Infection
AASLD LiverLearning®, Yoshihito Uchida, 144907
Community-Based Strategies to Improve Testing and Linkage to Care for Foreign-Born Persons with Chronic Hepatitis B Virus Infection
AASLD LiverLearning®, Aaron Harris, 144665
Incidence, predictors and outcome of ventilator associated pneumonia in critically ill cirrhotics admitted to a liver intensive unit.
AASLD LiverLearning®, AMRISH SAHNEY, 144923
Patients with HIV-HBV coinfection are an underestimated reservoir for Hepatitis Delta Virus. An analysis of the ICONA cohort
AASLD LiverLearning®, Giovanni Gaeta, 144681
Network Approach to unveil Molecular Pathways driving Cirrhosis progression to Acute-on-Chronic Liver Failure (ACLF)
AASLD LiverLearning®, Pere Gines, 144939
Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay
AASLD LiverLearning®, Noboru Shinkai, 144697
Alcohol-related acute on chronic liver failure- comparison of various prognostic scores in predicting outcome
AASLD LiverLearning®, . Shalimar, 144955
Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort
AASLD LiverLearning®, Segolene Brichler, 144714
Treatment of refractory ascites with the automated low-flow ascites pump: analysis of the surveillance database
AASLD LiverLearning®, Guido Stirnimann, 144971
Serum hepatitis B core-related antigen and surface antigen levels are correlated with hepatic fibrosis and inflammatory activity in treatment-naïve chronic hepatitis B patients
AASLD LiverLearning®, Tetsuya Hosaka, 144730
Emricasan (IDN-6556) Orally for 6 Months in Patients with Cirrhosis and Elevated MELD Score Improves Liver Function
AASLD LiverLearning®, Catherine Frenette, 144987
The effects of non-alcoholic fatty liver disease on liver fibrosis in chronic hepatitis B patients on nucleoside analogue therapy: results from a matched-case control study.
AASLD LiverLearning®, Wai-Kay Seto, 144746
Evaluation of Splenic Function in patients with Cirrhosis through observation of erythocytes with D.I.C. Microscopy.
AASLD LiverLearning®, Themistoklis Vasileiadis, 145003
A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144
AASLD LiverLearning®, Jinghang Xu, 144762
Post-treatment dynamic changes of liver stiffness to predict first 2-year outcomes in HBV compensated cirrhosis
AASLD LiverLearning®, Hong You, 144779
Introducing the Australasian Hepatology Association’s Consensus Guidelines for the Provision of Adherence Support to People with Hepatitis C taking Direct Acting Antivirals
AASLD LiverLearning®, Jacqueline Richmond, 144537
Nutritional Assessment Tools as Prognostic Tools in Cirrhotic Patients
AASLD LiverLearning®, Meri Koulentaki, 144538
Elevated WFA+M2BP, ALT flare and HBs decline>1.0Log/ml during Peg IFN were predict drug free and HBs antigen clearance in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients
AASLD LiverLearning®, Miwa Kawanaka, 144795
Frequency of CCR7-PD-1+ follicular helper T cell subset as a possible diagnostic marker of autoimmune hepatitis
AASLD LiverLearning®, Satoshi Yamagiwa, 144553
Vitamin D Deficiency is Associated with Progression to Cirrhosis and Decompensation in Patients with Autoimmune Hepatitis
AASLD LiverLearning®, Rahima Bhanji, 144554
Preliminary Results from TOPAZ-III, A Phase 3b Study Evaluating the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin in Naive or Experienced Adults in Brazil with HCV Genotype 1 Infection and Advanced Fibrosis/Cirrhosis
AASLD LiverLearning®, Mário Pessôa, 144811
Bioinformatic Identification and Validation of C1QTNF2 as a Candidate Antifibrotic Molecule in Hepatic Stellate Cells
AASLD LiverLearning®, Daniel Hicks, 144569
25(OH) D3 alleviate liver NK cytotoxicity in early but not in late fibrosis model of Balb/c mice due to modulations in vitamin D receptor
AASLD LiverLearning®, Johnny Amer, 144570
Effectiveness of Ledipasvir/Sofosbuvir±Ribavirin and Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin in 996 Genotype 1 HIV/HCV Coinfected Patients Treated in Routine Practice
AASLD LiverLearning®, Pamela Belperio, 144827
Correlation of Cytoglobin Level in Stellate Cells with Promotion or Attenuation of Liver Fibrosis and Cancer in Mice
AASLD LiverLearning®, Thuy Le, 144585
Use of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients with Advanced Chronic Kidney Disease (eGFR ≤ 30ml/min): A Case Series
AASLD LiverLearning®, Thomas McQuaid, 144843
Vibration-Controlled Transient Elastography (VCTE) is Useful in Identifying Clinically Significant Portal Hypertension in Patients with NASH Cirrhosis
AASLD LiverLearning®, Raj Vuppalanchi, 144601
Efficacy and tolerability of IFN-free direct acting antivirals therapy (daclatasvir and asunaprevir) in chronic hemodialysis patients with chronic hepatitis C
AASLD LiverLearning®, Goki Suda, 144859
Hepatitis E infection in a large cohort of solid organ and stem cell recipients prior to transplantation
AASLD LiverLearning®, Jordi Llaneras Artigues, 144617
Difference of serum 4β-hydroxycholesterol level, a surrogate marker of CYP3A activity, among patients with chronic HCV infection
AASLD LiverLearning®, Tadashi Ikegami, 144875
Differences in Hepatocellular Carcinoma Incidence and Survival Rates among Asian Mono-Ethnicities
AASLD LiverLearning®, George Cholankeril, 144633
Treatment Patterns Among Hepatitis C Virus Genotype 3 Patients in the United States
AASLD LiverLearning®, Lisa Rosenblatt, 144891